News

In this role, Dr Vaishnaw will be responsible for continued leadership of the company’s clinical activities; he will continue to report to John Maraganore, Alnylam’s CEO. Dr Vaishnaw

This agreement is in addition to the prior one announced in July 2007 to develop a novel stent system for coronary artery disease, which is now in clinical

The RFD submission is part of a process with the FDA for determining which agency component will have primary jurisdiction for a drug, device or biological product. The

As BaroFold’s new president and CEO, Dr Freytag brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Dr Freytag served as chairman

The Peak surgery system includes the Pulsar generator and the Peak PlasmaBlade family of disposable, low-temperature surgical cutting and coagulation devices. The generator provides pulsed plasma radiofrequency energy

The minimum total value of these contracts is $650,000 and $210,000 respectively. These new orders bring the minimum total value of pharmaceutical clinical trial contracts secured by AtCor

Under the terms of the seven-year agreement, LeMaitre Vascular has exclusive rights to market and sell certain sizes of Neovasc’s tissue patch products used for vascular surgery in

Mr Billings is a founding partner at Atwater Financial Group, a Montreal-based financial consultancy group. Mr Billings is also the president and CEO of Orex Exploration, a junior

Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis and Nisisco, Ipsen’s new agreement strengthens the commitment of